Kronos Bio, Inc. is a clinical development biopharmaceutical company. The company is headquartered in San Mateo, California and currently employs 10 full-time employees. The company went IPO on 2020-10-09. The firm is focused on developing therapeutics that target the deregulated transcription that causes cancer and other serious diseases. The company is developing KB-0742, its internally discovered oral cyclin dependent kinase 9 (CDK9) inhibitor, for the treatment of MYC-amplified and others transcriptionally addicted solid tumors. The company has initiated the Phase 2 portion of its Phase 1/2 clinical trial for KB-0742. The company is also developing KB-9558, which inhibits the lysine acetyltransferase (KAT) domain of p300, a critical node of the IRF4 TRN. IRF4 is a key transcription factor driver in multiple myeloma and KB-9558 selectively targets its activity. Its scientific focus is on developing medicines that target deregulated transcription, the hallmark of cancer and other serious diseases. Using its Small Molecule Microarray (SMM) platform or other approaches, it can generate and advance small molecule starting points into drug development candidates.